InQ Biosciences Announces New Board Members

InQ Biosciences Announces New Board Members


HUNTSVILLE, Ala., Nov. 22, 2010 /PRNewswire/ -- InQ Biosciences Corporation, a provider of innovative technologies for cell growth and research, announced that Michael Chambers and John R. Cooper have been appointed to the board of directors.

"Michael and John bring successful leadership and deep experience in life science and technology to the Board. We look forward to applying their spirit of innovation and success to the growth of InQ Biosciences," said Dick Reeves, chairman and chief executive officer, InQ Biosciences.

Michael Chambers, Ph.D. is President and CEO of Swift Biotechnology, an emerging company targeting development of cancer diagnostics. He actively invests in early-stage high-growth companies and serves on the board of ProUroCare, a publicly traded company. Previously, Chambers helped establish InnoRx Pharmaceuticals in 1999, a company specializing in development of drugs and drug delivery systems for ocular disease. He served as president and CEO of InnoRx until negotiating its sale and merger into SurModics.

John Cooper is the retired chairman and CEO of publicly traded Avocent Corporation. From 2002 until 2008, he led Avocent through a period of rapid growth to become one of the largest companies in local and remote IT infrastructure management. From 1996 to 2001, Mr. Cooper was chief financial officer and senior vice president for finance and administration, of publicly traded ADTRAN, Inc., a leading global provider of networking and telecommunications solutions with revenues of $300 million.

InQ Biosciences provides the InQTM Cell Research System, the first fully integrated system that creates an in vivo-like environment for studying sensitive nerve, brain, and other human cells for disease research. It is the only cell research instrument that combines a dynamic software-controlled sample environment with powerful imaging and real-time data collection. These unique capabilities enable researchers to achieve unprecedented cell culture control, viability, and visibility that was previously unattainable.

About InQ Biosciences

InQ Biosciences is a provider of innovative technologies for cell growth and research. The company's InQ Cell Research System will empower scientists to unlock novel and more powerful approaches to cell-based discovery. The firm was founded in 2007 with technology originating from the University of Alabama in Huntsville. Series B financing was completed in May 2010 and commercial launch of its InQ system is scheduled for the fourth quarter of 2010. For more information, visit www.inqbio.com. Follow InQ Biosciences on Twitter at @InQbio (http://twitter.com/InQbio).

SOURCE InQ Biosciences Corporation

Suggested Articles

PureTech Health has decamped from Cambridge to Boston’s Seaport neighborhood as a step toward growing the company and ramping up its pipeline.

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.